HOME ·

01779.HK

LONGBIO-B (01779.HK): Shares included in eligible securities list under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect
Tags：
LongBio-BStock Connect01779.HK
2026-09-07
LONGBIO-B (01779.HK): BLA of LP-003 for seasonal allergic rhinitis accepted by NMPA
Tags：
LongBio-B01779.HKClinical Progress
2026-08-21
LongBio Pharma-B (01779.HK) to Introduce Long-term Incentive Mechanism, Plan Cap Not Exceeding 10% of Issued Shares
Tags：
LongBio Pharma01779.HK
2026-07-16
LONGBIO-B (01779.HK): Anti-IgE Antibody LP-003 Receives FDA Clinical Trial Clearance for Peanut Allergy
Tags：
LongBio-B01779.HKClinical Trial
2026-07-13
LongBio Pharma(01779.HK): Over-Allotment Option Fully Exercised, Raising Additional Net Proceeds of Approximately HK$194 Million
Tags：
LongBio Pharma01779.HK
2026-07-01
LongBio Pharma-B(01779.HK): LP-003 Phase III Trial for Seasonal Allergic Rhinitis Hits Primary Endpoint
Tags：
LongBio Pharma-B01779.HKClinical Trial
2026-06-12
LONGBIO-B(01779.HK)Rises 37.21% on Listing Day to Close at HK$131.8
Tags：
LongBio-B01779.HKListingDebut
2026-06-05
LongBio Pharma-B(01779.HK): Public Subscription Opens Today, Entry Fee Approx. HK$4,851; Cornerstone Investors Pledge About US$8.7 Million
Tags：
LongBio Pharma-B01779.HKpublic subscriptionIPO
2026-05-28